RA PHARMACEUTICALS INC's ticker is RARX and the CUSIP is 74933V108. A total of 59 filers reported holding RA PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $3,573,000 | -27.0% | 74,447 | -28.6% | 0.00% | 0.0% |
| Q4 2019 | $4,894,000 | +171.0% | 104,269 | +36.5% | 0.00% | 0.0% |
| Q3 2019 | $1,806,000 | +26.1% | 76,365 | +60.3% | 0.00% | – |
| Q2 2019 | $1,432,000 | +79.4% | 47,635 | +33.7% | 0.00% | – |
| Q1 2019 | $798,000 | -4.7% | 35,625 | -22.5% | 0.00% | – |
| Q4 2018 | $837,000 | +510.9% | 45,980 | +505.4% | 0.00% | – |
| Q3 2018 | $137,000 | -73.0% | 7,595 | -85.1% | 0.00% | – |
| Q2 2018 | $508,000 | +527.2% | 51,087 | +235.8% | 0.00% | – |
| Q1 2018 | $81,000 | -58.0% | 15,213 | -33.0% | 0.00% | – |
| Q4 2017 | $193,000 | -44.5% | 22,691 | -4.8% | 0.00% | – |
| Q3 2017 | $348,000 | +107.1% | 23,842 | +166.2% | 0.00% | – |
| Q2 2017 | $168,000 | -16.8% | 8,957 | -5.3% | 0.00% | – |
| Q1 2017 | $202,000 | +254.4% | 9,455 | +151.8% | 0.00% | – |
| Q4 2016 | $57,000 | – | 3,755 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 6,138,797 | $294,724,000 | 15.40% |
| RA Capital Management | 4,858,260 | $233,245,000 | 7.37% |
| HAVENS ADVISORS LLC | 143,266 | $6,878,000 | 6.70% |
| BARDIN HILL MANAGEMENT PARTNERS LP | 609,614 | $29,267,000 | 6.40% |
| OMNI PARTNERS LLP | 1,052,744 | $50,542,000 | 4.45% |
| HBK INVESTMENTS L P | 2,004,042 | $96,214,000 | 4.03% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,005,600 | $96,289,000 | 3.83% |
| Versor Investments LP | 1,108,845 | $53,236,000 | 3.53% |
| OXFORD ASSET MANAGEMENT LLP | 461,016 | $22,133,000 | 3.12% |
| HighVista Strategies LLC | 63,222 | $3,035,000 | 2.81% |